Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032045 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00032045: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00032045 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032045, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining vaccine therapy with a monoclonal antibody may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with monoclonal antibody therapy in treating patients who have stage IV melanoma.
Interventions
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032045
The ClinicalTrials.gov registry entry for NCT00032045 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which incomplete Freund's adjuvant is the first listed.
NCT00032045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00032045 about?
NCT00032045 is a clinical study titled "Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma". RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining vaccine therapy with a monoclonal antibody may ...
What is the current status of trial NCT00032045?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00032045?
The interventions under investigation include: incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL), ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00032045?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.